Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer

Cancer Immunology Immunotherapy(2021)10.1007/s00262-021-02936-1Source: DataRank Database

A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer is a research paper published in Cancer Immunology Immunotherapy (2021). On theSindex it has a DataRank of 0. It has been cited 13 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access13 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (14 grants)Impact (FWCI 0.88)OA: bronzeTopics (48)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Cheryl Eppolito,Anthony Miliotto,Kelly L. Singel ORCID,Kyle B. Stephenson,Amit A. Lugade

Live enrichment

PubMed:33880648 PMC:PMC8057655 OpenAlex:https://openalex.org/W3155027568

Ovarian Cancer Research Fund

Grant: 326870

National Institutes of Health

Grant: P50CA159981-01A1

National Institutes of Health

Grant: UO1 CA233085-01A1

National Institutes of Health

Grant: R01CA188900

National Institutes of Health

Grant: P30CA016056

National Institutes of Health

Grant: R03CA223623

NCI NIH HHS

Grant: U01 CA233085

NCI NIH HHS

Grant: P50 CA159981

National Institutes of Health

Grant: 5P30CA016056-40

Roswell Park Cancer Institute Cancer Center Support Grant

National Institutes of Health

Grant: 1R03CA223623-01

The role of CREB3L1 in synergy between oncolytic vaccinia virus and doxorubicin

National Institutes of Health

Grant: 1R01CA188900-01A1

Novel immunological biomarkers ovarian cancer prognosis

National Institutes of Health

Grant: 1P50CA159981-01A1

MHC-Restricted and MHC-Non-Restricted Targeting of Ovarian Cancer by alphaDC1

National Institutes of Health

Grant: 7U01CA233085-02

U01 Proposal Transfer - 2021

Roswell Park Cancer Institute

FWCI

0.88

Citation Percentile

0.7%

Citation Trend

2022

2023

2024

2025

bronzeLicense: Springer Nature TDM

journalhttps://link.springer.com/content/pdf/10.1007/s00262-021-02936-1.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s00262-021-02936-1.pdf

publisherhttps://link.springer.com/article/10.1007/s00262-021-02936-1/fulltext.html

journalhttps://doi.org/10.1007/s00262-021-02936-1

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33880648

Fields of Study

Immunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersImmune Cell Function and Interaction03 medical and health sciences0302 clinical medicine

MeSH Terms

Myeloid-Derived Suppressor CellsImmune Checkpoint InhibitorsAnimalsCombined Modality TherapyFemaleImmunotherapyOvarian NeoplasmsTumor Necrosis Factor Receptor Superfamily, Member 7CD8-Positive T-LymphocytesCancer VaccinesMiceProgrammed Cell Death 1 Receptor

Keywords

BlockadeMedicineOvarian cancerImmune checkpointImmunotherapyCancer immunotherapyContext (archaeology)CD8Cancer researchOncologyImmunologyCancerInternal medicineImmune systemBiologyCancer vaccineCD27MdscSuppressive Myeloid CellsOvarian NeoplasmsMyeloid-Derived Suppressor CellsProgrammed Cell Death 1 ReceptorCD8-Positive T-LymphocytesCancer VaccinesCombined Modality TherapyTumor Necrosis Factor Receptor Superfamily, Member 7MiceAnimalsOriginal ArticleFemaleImmune Checkpoint Inhibitors

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being